意大利DPYD与UGT1A1检测实施及药物遗传学指南依从性:EQA提供者5年视角
本研究分析2019至2023年意大利实验室参与EMQN药物遗传学EQA计划提交的88份关于氟尿嘧啶/DPYD和伊立替康/UGT1A1药物-基因相互作用的匿名临床报告。结果显示DPYD和UGT1A1检测采用率显著增加,SIF-AIOM基因分型面板使用率从2019年0%升至2023年97%,提供符合至少一部主要指南的准确临床解读的实验室比例从2021年34%升至2023年63%。等位基因鉴别成为首选基因分型方法,尤其伴随欧盟标记的体外诊断试剂盒的广泛采用。
要点
- 意大利实验室占欧洲提交量的45%,DPYD和UGT1A1检测采用率显著上升。
- SIF-AIOM基因分型面板使用率从2019年0%增至2023年97%。
- 准确临床解读(符合至少一部主要指南)比例从2021年34%升至2023年63%。
核心结论
- 意大利实验室在药物遗传学检测的准确性和指南依从性方面呈现改善趋势,反映临床药物遗传学实践的意识和协调性增强。
研究设计与样本
- 分析2019至2023年意大利实验室参与EMQN药物遗传学EQA计划提交的88份匿名临床药物遗传学报告,评估基因分型面板、方法、参考指南和临床解读准确性。
主要发现
- 5年期间意大利实验室占所有欧洲提交量的45%。
- SIF-AIOM基因分型面板使用率从2019年0%上升至2023年97%。
- 提供符合至少一部主要指南(CPIC、DPWG或SIF-AIOM)的准确临床解读的实验室比例从2021年34%增至2023年63%。
- 等位基因鉴别成为首选基因分型方法,尤其伴随欧盟标记的体外诊断试剂盒的广泛采用。
关键数值与推荐
- 仅SIF-AIOM指南推荐在反应性设置中检测DPYD*6变异,但需要更清晰的指导以避免患者治疗不足的风险。
临床怎么用
- 临床药物遗传学检测应参考主要指南(如CPIC、DPWG或SIF-AIOM)进行基因分型面板选择和临床解读。
- 在反应性设置中检测DPYD*6变异时需注意治疗不足风险,并寻求更清晰的指导。
局限性
- 研究仅基于参与EMQN药物遗传学EQA计划的意大利实验室提交的报告,可能不能代表所有意大利实验室的实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Pharmacogenetic implementation requires awareness of the state-of-the-art practice of laboratories providing pharmacogenetic testing. This study investigated how pharmacogenetic guidelines and recommendations have been implemented over time by Italian laboratories participating in the external quality assessment (EQA) Pharmaco-scheme established since 2019 by the European Molecular genetics Quality Network (EMQN). METHODS: Anonymized clinical pharmacogenetic reports submitted by Italian laboratories participating in the EMQN Pharmaco-scheme between 2019 and 2023 were analysed. A total of 88 reports addressing fluoropyrimidine/DPYD and irinotecan/UGT1A1 drug-gene interactions were evaluated for genotyping panel adopted and methodology, referenced guidelines and accuracy of clinical interpretation. RESULTS: Over the 5-year period, Italian laboratories accounted for 45% of all European submissions. The adoption of DPYD and UGT1A1 testing increased significantly, with the use of the Italian Society of Pharmacology - Italian Association of Medical Oncology (SIF-AIOM) genotyping panel rising from 0% in 2019 to 97% in 2023. The proportion of laboratories providing accurate clinical interpretations in line with at least one major guideline (the Clinical Pharmacogenetics Implementation Consortium, the Dutch Pharmacogenomics Working Group or SIF-AIOM) increased from 34% in 2021 to 63% in 2023. Notably, only the SIF-AIOM guidelines recommend testing for the DPYD*6 variant in a reactive setting. However, clearer guidance is needed to avoid the risk of undertreatment in these patients. Allelic discrimination emerged as the preferred genotyping method, particularly with the widespread adoption of commercial European Union-marked in vitro diagnostic kits. CONCLUSIONS: This study provides a snapshot of pharmacogenetic testing practices in Italian laboratories participating in an EQA programme. It highlights an encouraging trend toward improved accuracy and guideline adherence, reflecting increasing awareness and harmonization in clinical pharmacogenetic practice.
引用
- Roncato R, Perfler S, Pasin D, et al. Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider. Br J Clin Pharmacol. 2025. PMID: 40905546. doi:10.1002/bcp.70247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。